Beijing: Phase II clinical trials of the covid-19 vaccine being conducted in China have found that it is safe and is causing an immune response in the body. It has been said in a study published in The Lancet Medical Journal. Other scientists involved in the research, including experts from the China Centers for Disease Control, said the test evaluated vaccine safety and immunogenicity. He said that the results of the research have provided data from far more participants than the first stage test.
The trial also included a small group of people over 55 years of age. However, researchers cautioned that none of the participants in the current trial were exposed to the corona virus, SARS-CoV-2, after vaccination. Therefore, he said that it is not possible to say through the current testing whether the vaccine provided effective protection against SARS-CoV-2 infection.
According to scientists, 508 people were included in the new vaccine test.
Danny Altman, professor of immunology at Imperial College, London, UK, said, “China’s research is based on the common cold-cold virus against which antibodies already exist in people’s bodies.” “It is notable that he has no connection with the research team.
